Multiple Sclerosis (MS) is a chronic, lifelong disease of the nervous system characterised by demyelination of the nerve cells in the central nervous system. Demyelination is irreparable and can occur anywhere in the nervous system
Conditions
Interventions
The intervention consists of eight online, mindfulness-based sessions over an 8-week period. The content of the mindfulness sessions have been developed specifically for people living with MS and qual
and the programme consists of information, in-session activities, relevant mindfulness metaphors and mindfulness exercises. The MindfulnessforMS intervention has been developed into an online format b
the emails are not part of the treatment regimen. Adherence to the trial intervention will be monitored automatically via the online delivery platform and adh
Sponsors
Irish Health Research Board and the Medical Research Charities Group Joint Funding Scheme
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 years or more 2. Diagnosis of primary or secondary progressive MS 3. Internet access 4. Not currently undergoing any form of psychological treatment 5. First language English 6. Resident in Ireland, not currently experiencing a psychotic illness and/or cognitive impairment.
Exclusion criteria
Exclusion criteria: 1. Participants undergoing any form of psychological treatment 2. Participants experiencing a psychotic illness and/or cognitive impairment 3. Participation in any other form of psychological intervention in addition to the study intervention is prohibited during the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| General levels of distress are measured using the 12-item General Health Questionnaire (GHQ-12) at 3 time points such as week immediately pre intervention, during the week post intervention and at 3 month follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Severity of current symptoms of depressive disorders are measured using the Beck Depression Inventory (BDI) 3 time points such as week immediately pre intervention, during the week post intervention and at 3 month follow up 2. Pain severity and the degree of interference with function is measured using the Beck Pain Inventory short form (BPI-SF) at 3 time points such as week immediately pre intervention, during the week post intervention and at 3 month follow up 3. Health-related quality of life measured using the EQ-5D at 3 time points such as week immediately pre intervention, during the week post intervention and at 3 month follow up 4. Impact of fatigue in the day-to-day functioning of patients is measured using the fatigue severity scale (FSS) at 3 time points such as week immediately pre intervention, during the week post intervention and at 3 month follow up 5. Anxiety is measured using the Generalised anxiety disorder 7-item scale (GAD-7) at 3 time points such as week immediately pre intervention, during the week post intervention and at 3 month follow up 6. Health related quality of life is measured using the medical outcomes short form-12 at 3 time points such as week immediately pre intervention, during the week post intervention and at 3 month follow up 7. Physical and psychological impact of MS is measured using the Multiple Sclerosis Impact Scale (MSIS-29) 3 time points such as week immediately pre intervention, during the week post intervention and at 3 month follow up 8. Medication and health service use is measured using the client service receipt inventory (CSRI) at baseline, post-treatment and follow up | — |
Countries
Ireland
Outcome results
None listed